益生菌改善代谢疾病相关指标
创作:海盗船长 审核:szx 2019年08月10日
  • 纳入105篇RCT(干预期14天以上,共6826名受试者)进行荟萃分析;
  • 益生菌可改善超重非肥胖患者的体重、BMI、腰围、体脂质量和内脏脂肪质量;
  • 益生菌可降低2型糖尿病患者的空腹血糖、糖化血红蛋白、胰岛素和胰岛素抵抗;
  • 益生菌可降低非酒精性脂肪性肝病(NAFLD)患者的丙氨酸和天冬氨酸转氨酶水平;
  • 改善效果主要来自短/长双歧杆菌、唾液链球菌嗜热亚种,嗜酸/干酪/德布鲁埃克氏乳杆菌;
  • 益生菌对代谢性疾病的风险因素具有改善作用。
主编推荐语
szx
BMJ Open上发表的一项荟萃分析结果,在超过100项RCT(近7000名患者)中发现,益生菌可改善超重、2型糖尿病及NAFLD患者的疾病相关指标。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
BMJ Open [IF:2.376]

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

益生菌对肥胖、糖尿病和非酒精性脂肪性肝病相关变量的影响:一项随机对照试验的系统回顾和荟萃分析

10.1136/bmjopen-2017-017995

2019-03-30, Article

Abstract & Authors:展开

Abstract:收起
Objective : To systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.
Design: Systematic review and meta-analysis.
Data sources: Medline, EMBASE and COCHRANE from 1990 to June 2018.
Eligibility criteria: Randomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.
Results : One hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body mass index (k=32, d=−0.55 kg/m², 95% CI −0.86 to −0.23, I²=91.9%), waist circumference (k=13, d=−1.31 cm, 95% CI −1.79 to −0.83, I²=14.5%), body fat mass (k=11, d=−0.96 kg, 95% CI −1.21 to −0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=−6.30 cm², 95% CI −9.05 to −3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=−0.66 mmol/L, 95% CI −1.00 to −0.31, I²=27.7%), glycated haemoglobin (k=13, d=−0.28 pp, 95% CI −0.46 to −0.11, I²=54.1%), insulin (k=13, d=−1.66 mU/L, 95% CI −2.70 to −0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=−1.05 pp, 95% CI −1.48 to −0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=−10.2 U/L, 95% CI −14.3 to −6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=−9.9 U/L, 95% CI −14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country.
Conclusions : The intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases.

First Authors:
Hana Koutnikova

Correspondence Authors:
Karine Clément

All Authors:
Hana Koutnikova,Bernd Genser,Milena Monteiro-Sepulveda,Jean-Michel Faurie,Salwa Rizkalla,Jürgen Schrezenmeir,Karine Clément

图片
Gut Microbiota for Health新闻网站

Probiotics could help treat metabolic disease patients

Allison Clark,2019-07-24

评论